Department of Otorhinolaryngology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY.
J Surg Oncol. 2020 Jun;121(7):1058-1066. doi: 10.1002/jso.25895. Epub 2020 Mar 9.
The number of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) at an advanced age has increased. The aim of this study is to evaluate the age at which disease-specific survival (DSS) significantly decreases in HNSCC.
We performed a retrospective study of 5469 patients with HNSCC treated at our center (1985-2016). External validation with 2082 oral squamous cell carcinomas from a collaborative institution from another continent was performed.
We observed an orderly decrease in overall survival as age at diagnosis increased. There were no differences in DSS based on age for patients <80 years old (P = .623), while older patients had a significant decrease in DSS. These results were validated in the independent dataset. In a multivariable analysis performed in the test set, compared to patients <80 years old, patients between 80 to 85 had a 1.50 times higher risk of disease-specific death (95% confidence interval [CI]: 1.19-1.89; P = .001), and patients >85 had a 2.19 times higher risk (95% CI: 1.68-2.87; P < .001).
DSS started to significantly decrease in HNSCC at 80 years old. These findings, validated in an independent cohort, indicate that chronological age on its own should not withhold curative treatment in the majority of patients with HNSCC.
诊断为头颈部鳞状细胞癌(HNSCC)的老年患者数量有所增加。本研究旨在评估 HNSCC 患者疾病特异性生存率(DSS)显著下降的年龄。
我们对在我院(1985-2016 年)治疗的 5469 例 HNSCC 患者进行了回顾性研究。并对来自另一大洲合作机构的 2082 例口腔鳞状细胞癌患者进行了外部验证。
我们观察到随着诊断时年龄的增加,总生存率呈有序下降。对于<80 岁的患者,DSS 与年龄无关(P = .623),而年龄较大的患者 DSS 显著下降。这些结果在独立数据集得到了验证。在检验集中进行的多变量分析中,与<80 岁的患者相比,80-85 岁的患者疾病特异性死亡的风险增加了 1.50 倍(95%置信区间[CI]:1.19-1.89;P = .001),>85 岁的患者风险增加了 2.19 倍(95% CI:1.68-2.87;P < .001)。
DSS 在 80 岁时开始对头颈部鳞状细胞癌患者显著下降。这些在独立队列中得到验证的发现表明,在大多数 HNSCC 患者中,仅根据年龄本身不应拒绝根治性治疗。